Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion is an attractive investment opportunity with a strong pipeline of clinical-stage vaccines in both oncology and infectious diseases, backed by its proprietary AI-Immunology platform. The company has a well-established executive team, led by a CEO with a track record of successful partnerships. With an impressive 86% immunogenic neoantigen rate and potential partnerships in the near future, we maintain a positive outlook on Evaxion's stock and have a 12-month price target of $16.00 per share. However, risks such as competition and regulatory concerns could impact the company's success.

Bears say

Evaxion is utilizing their proprietary AI-Immunology platform to develop novel vaccines for both cancer and infectious diseases with a high unmet medical need. With positive preclinical data for their lead candidate, EVX-04, the company is transitioning towards a scalable and off-the-shelf alternative to personalized cancer vaccines, addressing scalability and time-to-treatment concerns. However, with an estimated IND filing in the second half of 2026, there may be a longer wait time for potential revenue and profitability from their pipeline.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of May 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.